. Author manuscript; available in PMC: 2023 Oct 31.

Published in final edited form as: Br J Haematol. 2020 Jun 9;192(3):484–493. doi: 10.1111/bjh.16808

Table IV.

Summary of major T-LGLL studies.

Reference	Year	Prospective trial	Patients, n	Presenting anaemia, %	Presenting neutropenia, %	Autoimmune disease, %	Rheumatoid arthritis, %	Splenomegaly, %	Concomitant malignancy, %	Response rates (MTX, Cy, CsA), %	Alemtuzumab response, %	OS (5 years), %
Present study	2020	No	60	41	26	37	27	28	18	38, ND, 22	50	72
Semenzato et al.³	1997	No	162	26	ND	ND	36	50	ND	ND	ND	ND
Neben et al.²⁹	2003	No	44	52	89	ND	20	35	ND	ND	ND	ND
Bareau et al.¹⁹	2010	No	201	61	24	ND	17	24	ND	55, 66, 21	ND	89
ECOG 5998 study²²	2015	Yes	55	53	47	ND	7	ND	ND	38, 64 (2nd line)	ND	69, 76 months^*
Moignet et al.¹⁸	2014	No	45	53	24	11	2	ND	ND	ND, 71, ND	ND	ND
Dumitriu et al.²⁴	2016	No	25	44	72	ND	ND	2	ND	ND	56	ND

ND, no data.

Patients with anaemia had a median OS of 69 months, whereas patients with neutopenia had a median OS of 76 months.